This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Acadra

Advancell - Advanced In Vitro Cell Technologies, S.A.

Drug Names(s): ATH001

Description: Acadra appears to be acadesine (also called 5-aminoimidazole-4-carboxamide-1-ß-D-ribofuranoside, AICA-riboside, and AICAR), an AMP-activated protein kinase that plays a role in cellular energy homeostasis.

Acadra is believed to selectively induce apoptosis to B-cell leukemia cells with a mechanism independent of p53 status, and thus eliminates B-cells without affecting T cells, thus preserving overall immunity.

Studies have shown that Acadra elicits anticancer activity in patients carrying high-risk genetic factors such as 17p13 deletions and unmutated IgVH.

Deal Structure: Advancell and Protherics (BTG)
In December 2006, Advancell and Protherics entered into a licensing and co-development agreement with Advancell for the treatment of B-cell chronic lymphocytic leukemia.

In December 2008, BTG announced that all the conditions to its recommended offer for Protherics have been satisfied and the Acquisition has therefore been completed.

In November 2009, Advancell licensed-backed its rights from Protherics (BTG) of Acadra which was in co-development for the treatment of B-cell chronic lymphocytic leukemia.


Acadra News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug